Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard J Lin

Showing results (51-60 of 95) with videos related to

Pageof 10
Sort By:
Transplantation and Cellular Therapy|October 14, 2021
Hematopoietic Cell Transplantation is Feasible in Patients with Prior COVID-19 InfectionNishi Shah, Parastoo B Dahi, Doris M Ponce, et al.
Journal of Geriatric Oncology|August 20, 2025
Aging-related, senescence-associated secretory phenotype and allogeneic hematopoietic cell transplantation outcomes in older patientsMark Y Jeng, Phillip Wong, Jessica R Flynn, et al.
Haematologica|July 22, 2021
Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphomaRichard J Lin, Colette N Owens, Esther Drill, et al.
Transplantation and Cellular Therapy|October 24, 2024
Shift from Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T Cell Therapy: Results from a Large Retrospective CohortGiovanna Melica, Alejandro Luna de Abia, Gunjan L Shah, et al.
Bone Marrow Transplantation|October 25, 2019
Favorable long-term outcomes of hematopoietic stem cell transplantation for CMML with myeloablative conditioning, anti-thymocyte globulin, and CD34<sup>+</sup> selected graftRichard J Lin, Matias Sanchez, Kamal Abbi, et al.
Bone Marrow Transplantation|September 1, 2019
Impact of geriatric vulnerabilities on allogeneic hematopoietic cell transplantation outcomes in older patients with hematologic malignanciesRichard J Lin, Theresa A Elko, Sean M Devlin, et al.
Nature Medicine|July 3, 2023
CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim resultsJae H Park, Karthik Nath, Sean M Devlin, et al.
Blood Advances|January 5, 2019
Burden and impact of multifactorial geriatric syndromes in allogeneic hematopoietic cell transplantation for older adultsRichard J Lin, Patrick D Hilden, Theresa A Elko, et al.
Blood Advances|October 14, 2022
Analysis of disparities in time to allogeneic transplantation in adults with acute myelogenous leukemiaWarren B Fingrut, Boglarka Gyurkocza, Jessica Flynn, et al.
Bone Marrow Transplantation|November 18, 2025
Late hematologic toxicity after CAR T-cell therapy in large B-cell lymphoma: incidence, risk factors, and clinical impactMagdalena Corona, Samantha Brown, Kai Rejeski, et al.
Pageof 10

Showing results (51-60 of 95) with videos related to

Sort By:
Pageof 10
Transplantation and Cellular Therapy|October 14, 2021
Hematopoietic Cell Transplantation is Feasible in Patients with Prior COVID-19 InfectionNishi Shah, Parastoo B Dahi, Doris M Ponce, et al.
Journal of Geriatric Oncology|August 20, 2025
Aging-related, senescence-associated secretory phenotype and allogeneic hematopoietic cell transplantation outcomes in older patientsMark Y Jeng, Phillip Wong, Jessica R Flynn, et al.
Haematologica|July 22, 2021
Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphomaRichard J Lin, Colette N Owens, Esther Drill, et al.
Transplantation and Cellular Therapy|October 24, 2024
Shift from Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T Cell Therapy: Results from a Large Retrospective CohortGiovanna Melica, Alejandro Luna de Abia, Gunjan L Shah, et al.
Bone Marrow Transplantation|October 25, 2019
Favorable long-term outcomes of hematopoietic stem cell transplantation for CMML with myeloablative conditioning, anti-thymocyte globulin, and CD34<sup>+</sup> selected graftRichard J Lin, Matias Sanchez, Kamal Abbi, et al.
Bone Marrow Transplantation|September 1, 2019
Impact of geriatric vulnerabilities on allogeneic hematopoietic cell transplantation outcomes in older patients with hematologic malignanciesRichard J Lin, Theresa A Elko, Sean M Devlin, et al.
Nature Medicine|July 3, 2023
CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim resultsJae H Park, Karthik Nath, Sean M Devlin, et al.
Blood Advances|January 5, 2019
Burden and impact of multifactorial geriatric syndromes in allogeneic hematopoietic cell transplantation for older adultsRichard J Lin, Patrick D Hilden, Theresa A Elko, et al.
Blood Advances|October 14, 2022
Analysis of disparities in time to allogeneic transplantation in adults with acute myelogenous leukemiaWarren B Fingrut, Boglarka Gyurkocza, Jessica Flynn, et al.
Bone Marrow Transplantation|November 18, 2025
Late hematologic toxicity after CAR T-cell therapy in large B-cell lymphoma: incidence, risk factors, and clinical impactMagdalena Corona, Samantha Brown, Kai Rejeski, et al.
Pageof 10